National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Asthma: Relvar™ Ellipta™ is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta-2-agonist.

COPD: Relvar™ Ellipta™ is indicated for symptomatic treatment of patients with COPD with a FEV1<70% of predicted normal (post-bronchodilator) in patients with an exacerbation history despite regular bronchodilator therapy.

Rapid Review

Commenced Completed Outcome
10/12/2013 23/12/2013 Full Pharmacoeconomic Evaluation not Recommended.